Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Treatment of Pegylated Asparaginase-Induced Hypertriglyceridemia with Continuous Intravenous Infusion of Insulin and Heparin: A Case Report.

Alakel N, Heuschkel S, Balaian E, Röllig C, Bornhäuser M.

Chemotherapy. 2019;64(4):210-214. doi: 10.1159/000505773. Epub 2020 Feb 11.

PMID:
32045924
2.

Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes.

Balaian E, Weidner H, Wobus M, Baschant U, Jacobi A, Mies A, Bornhäuser M, Guck J, Hofbauer LC, Rauner M, Platzbecker U.

Ann Hematol. 2019 Sep;98(9):2063-2072. doi: 10.1007/s00277-019-03756-1. Epub 2019 Jul 16.

PMID:
31312928
3.

Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathway.

Balaian E, Wobus M, Weidner H, Baschant U, Stiehler M, Ehninger G, Bornhäuser M, Hofbauer LC, Rauner M, Platzbecker U.

Haematologica. 2018 Jan;103(1):61-68. doi: 10.3324/haematol.2017.172726. Epub 2017 Oct 27.

4.

Myelodysplastic syndromes and bone loss in mice and men.

Weidner H, Rauner M, Trautmann F, Schmitt J, Balaian E, Mies A, Helas S, Baschant U, Khandanpour C, Bornhäuser M, Hofbauer LC, Platzbecker U.

Leukemia. 2017 Apr;31(4):1003-1007. doi: 10.1038/leu.2017.7. Epub 2017 Jan 11. No abstract available.

PMID:
28074069
5.

Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2.

Francke S, Mies A, Meggendorfer M, Oelschlaegel U, Balaian E, Gloaguen S, Haferlach T, Ehninger G, Bornhäuser M, Platzbecker U.

Leuk Lymphoma. 2017 May;58(5):1271-1272. doi: 10.1080/10428194.2016.1225209. Epub 2016 Sep 23. No abstract available.

PMID:
27659716
6.

Wnt5a is a key target for the pro-osteogenic effects of iron chelation on osteoblast progenitors.

Baschant U, Rauner M, Balaian E, Weidner H, Roetto A, Platzbecker U, Hofbauer LC.

Haematologica. 2016 Dec;101(12):1499-1507. Epub 2016 Aug 18.

7.

Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q.

Balaian E, Schuster C, Schönefeldt C, Germing U, Haase D, Tuve S, Ordemann R, Ehninger G, Bornhäuser M, Oelschlaegel U, Mohr B, von Bonin M, Platzbecker U, Wermke M.

Ann Hematol. 2016 Oct;95(11):1805-10. doi: 10.1007/s00277-016-2775-y. Epub 2016 Aug 10.

PMID:
27510179
8.

Effects of a home-based exercise program on physical capacity and fatigue in patients with low to intermediate risk myelodysplastic syndrome-a pilot study.

Schuler MK, Hentschel L, Göbel J, Balaian E, Hornemann B, Hoffmann J, Kramer M, Kasten P, Bornhäuser M, Ehninger G, Platzbecker U.

Leuk Res. 2016 Aug;47:128-35. doi: 10.1016/j.leukres.2016.05.022. Epub 2016 May 27.

PMID:
27326698
9.

Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure.

Mossner M, Jann JC, Wittig J, Nolte F, Fey S, Nowak V, Obländer J, Pressler J, Palme I, Xanthopoulos C, Boch T, Metzgeroth G, Röhl H, Witt SH, Dukal H, Klein C, Schmitt S, Gelß P, Platzbecker U, Balaian E, Fabarius A, Blum H, Schulze TJ, Meggendorfer M, Haferlach C, Trumpp A, Hofmann WK, Medyouf H, Nowak D.

Blood. 2016 Sep 1;128(9):1246-59. doi: 10.1182/blood-2015-11-679167. Epub 2016 Jun 6.

PMID:
27268087

Supplemental Content

Loading ...
Support Center